Alzheimer Disease
📧 Sign up to get email alerts when something new happens for Alzheimer Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-04-03FDA Approved: MEMANTINE HYDROCHLORIDE — Original Application (Carlsbad Technology, Inc.)
The FDA approved an original application for memantine hydrochloride by Carlsbad Technology, Inc. The drug is a generic version of memantine…
-
CLINICAL_TRIALS trial_result · 2020-03-30Clinical Trial Update: aeRobic Exercise and Cognitive Health [NA]
A completed clinical trial investigating the effects of aerobic exercise on cognitive health in adults, with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-03-25Clinical Trial Update: Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease [Phase 2]
Phase 2 clinical trial update reporting on efficacy and safety of AD-35 in adults with mild to moderate Alzheimer's Disease.
-
CLINICAL_TRIALS trial_result · 2020-03-23Clinical Trial Update: A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease [Phase 1, Phase 2]
A randomized SAD and MAD study assessing safety and tolerability of RPh201 in healthy volunteers and adults with Alzheimer's disease; comple…
-
FDA approval · 2020-03-18FDA Approved: MEMANTINE HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approves Amneal Pharmaceuticals' supplemental ANDA for memantine hydrochloride, a generic memantine product for the treatment of symptom…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-03-16Clinical Trial Update: Alzheimer's Family Caregiver Intervention in Vietnam [NA]
A completed clinical trial assessing an Alzheimer's disease caregiver intervention in Vietnam; results posted in 2020.
-
FDA approval · 2020-03-15FDA Approved: MEMANTINE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for memantine hydrochloride from Rising Pharma Holdings, Inc.
-
FDA approval · 2020-03-15FDA Approved: MEMANTINE HYDROCHLORIDE — Supplemental Application (Zydus Lifesciences Limited)
The FDA approved a supplemental application for memantine hydrochloride filed by Zydus Lifesciences Limited. This action relates to the appr…
-
CLINICAL_TRIALS trial_result · 2020-03-12Clinical Trial Update: Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination [Phase 2]
Phase 2 clinical trial update exploring neuroimage PET probes (18F-PM-PBB3 and 18F-florbetapir) for Alzheimer's disease.
-
CLINICAL_TRIALS trial_result · 2020-03-09Clinical Trial Update: A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease [Phase 2]
Phase 2 trial evaluating pimavanserin for agitation and aggression in Alzheimer's disease has completed with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-02-17Clinical Trial Update: Transcranial Electromagnetic Treatment (TEMT) Against Alzheimer's Disease [Phase 1, Phase 2]
A clinical trial update for Transcranial Electromagnetic Treatment (TEMT) targeting Alzheimer's disease across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2020-02-12Clinical Trial Update: A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab [Phase 2]
Phase 2 long-term safety extension study for crenezumab in mild to moderate Alzheimer's disease completed; results posted.
-
CLINICAL_TRIALS trial_result · 2020-02-11Clinical Trial Update: To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients [Phase 2]
A Phase 2 clinical trial evaluated the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with Alzheimer's di…
-
CLINICAL_TRIALS trial_result · 2020-02-11Clinical Trial Update: Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients. [Phase 2]
Phase 2 clinical trial assessing safety and tolerability of repeated subcutaneous injections of CAD106 in patients with Alzheimer's disease …
-
CLINICAL_TRIALS trial_result · 2020-02-10Clinical Trial Update: An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia [Phase 2, Phase 3]
A Phase 2/3 trial of atabecestat in asymptomatic individuals at risk for Alzheimer's dementia was terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2020-01-31Clinical Trial Update: The Efficacy of Traditional Chinese Herbal Medicine for Alzheimer's Disease [Phase 1, Phase 2]
A clinical trial update evaluating traditional Chinese herbal medicine for Alzheimer disease across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2020-01-30Clinical Trial Update: A Noval Tau Tracer in Young Onset Dementia [Phase 1, Phase 2]
Clinical trial update on a novel tau tracer for young onset dementia, currently in Phase 1/Phase 2.
-
CLINICAL_TRIALS trial_result · 2020-01-22Clinical Trial Update: Alzheimer's Disease: Potential Benefit of Isoflavones [Phase 2]
Phase 2 clinical trial evaluating potential benefit of isoflavones in Alzheimer's disease completed with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-01-21Clinical Trial Update: Investigating the Clinical Consequences of Flutemetamol-PET-scanning [Phase 3]
Phase 3 study investigating clinical consequences of Flutemetamol-PET scanning was terminated.
-
CLINICAL_TRIALS trial_result · 2020-01-13Clinical Trial Update: Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients [Phase 2]
Phase 2 trial evaluation of UB-311 in mild Alzheimer's disease completed with results posted.
-
FDA approval · 2020-01-10FDA Approved: VIZAMYL — Supplemental Application (GE Healthcare Inc. (Medi-Physics, Inc. dba GE Healthcare))
FDA approved a supplemental application for Vizamyl (flutemetamol F-18) from GE Healthcare, expanding its regulatory authorization to includ…
-
FDA approval · 2020-01-10FDA Approved: NEURACEQ — Supplemental Application (Lantheus Biosciences Ltd.)
FDA approved a supplemental application for NEURACEQ (florbetaben F-18) from Lantheus Biosciences Ltd., granting continued approval for its …
-
FDA approval · 2019-12-30FDA Approved: DONEPEZIL HYDROCHLORIDE — Supplemental Application (Hisun Pharmaceuticals USA, Inc.)
FDA approved Hisun Pharmaceuticals USA, Inc.'s supplemental application for donepezil hydrochloride, a generic medication for the treatment …
-
FDA approval · 2019-12-20FDA Approved: AMYVID — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for AMYVID (Florbetapir F 18) from Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2019-12-11Clinical Trial Update: Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease [Phase 2]
Phase II study of intravenous immunoglobulin (IVIg) for Alzheimer's disease was terminated; results posted in 2019.